Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 ...

While diet and exercise remain the foundation for many, more and more stars are openly admitting to using weight-loss ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

Fans rubbed their eyes in disbelief after Meghan Trainor shared a video of herself attempting a wild and risky challenge ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

GLP-1 agonist users had a 17% lower cancer risk compared to non-users in a large retrospective study. The reductions achieved ...

Serena Williams opens up about her weight loss struggles and the use of GLP-1 medications, highlighting issues of access and ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication ...